Your session is about to expire
← Back to Search
Other
Single Arm Study Group for Prostate Cancer
Phase 3
Waitlist Available
Led By Vipul R Patel, MD
Research Sponsored by AdventHealth
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days to 12 months post prostatectomy
Awards & highlights
Summary
This trial is testing BioDFence® G3, a special amniotic membrane, on prostate cancer patients having robotic-assisted surgery. The goal is to see if it helps them recover sexual and urinary functions more quickly by protecting and healing tissues during the operation.
Eligible Conditions
- Prostate Cancer
- Prostatectomy
- Erectile Dysfunction
- Urinary Incontinence
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 14 days to 12 months post prostatectomy
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days to 12 months post prostatectomy
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Time to potency
Secondary outcome measures
Time to continence
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single Arm Study GroupExperimental Treatment1 Intervention
Placement of a sheet of BioDFence G3 to the neurovascular bundle.
Find a Location
Who is running the clinical trial?
AdventHealthLead Sponsor
109 Previous Clinical Trials
30,405 Total Patients Enrolled
1 Trials studying Prostate Cancer
128 Patients Enrolled for Prostate Cancer
Integra LifeSciences CorporationIndustry Sponsor
85 Previous Clinical Trials
9,829 Total Patients Enrolled
1 Trials studying Prostate Cancer
240 Patients Enrolled for Prostate Cancer
Vipul R Patel, MDPrincipal InvestigatorAdventHealth
1 Previous Clinical Trials
100 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger